PharmaLogic Expands Radiopharmaceutical Footprint With New Atlanta Facility

Key Takeaways

• PharmaLogic invests $250M to expand US radiopharma capacity.
• New Atlanta plant boosts PET production for Southeast hospitals.
• Facility supports development of next‑generation radiopharmaceuticals.
• Network now exceeds 45 sites delivering 2.5M doses yearly.
• Localized manufacturing shortens delivery times for short‑half‑life drugs.

Pulse Analysis

The radiopharmaceutical market is entering a period of rapid growth, driven by the rise of precision oncology, cardiology and neurology diagnostics. PET agents, in particular, are prized for their ability to visualize disease at the molecular level, but their short half‑lives demand manufacturing close to the point of care. In the United States, a fragmented production landscape has created bottlenecks, prompting CDMOs to invest heavily in localized facilities that can meet rising demand while maintaining product integrity.

PharmaLogic’s $250 million investment underscores this strategic shift. By adding a state‑of‑the‑art PET plant in Atlanta, the company not only expands capacity but also creates a regional hub for next‑generation radiopharmaceutical research. The Southeast, home to a growing network of hospitals and imaging centers, will benefit from faster, more reliable deliveries, reducing wait times for critical scans and therapies. The Atlanta site complements PharmaLogic’s existing footprint—including facilities in Cincinnati, the Bronx, Salt Lake City and Los Angeles—bringing the total to over 45 locations that collectively ship more than 2.5 million doses each year.

Beyond immediate logistics, the expansion signals broader industry trends. Investors are increasingly viewing radiopharma manufacturing as a high‑margin, defensible niche, especially as regulatory pathways for theranostic agents mature. Companies that can pair large‑scale production with agile R&D capabilities are positioned to capture emerging market share in both diagnostic and therapeutic segments. PharmaLogic’s move therefore not only improves patient access but also reinforces its competitive edge in a sector poised for sustained, multi‑billion‑dollar growth.